Hafiza Hafsa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hafiza Hafsa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ali Aamir
Department of Paediatric Urology Sindh Institute of Urology and Transplantation (SIUT) Karachi Pakistan
2 shared publications - Abdullah Nadeem
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Areeba Aamir Ali Basaria
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Atiqullah Sadaqat
Department of Curative Medicine, Faculty of Medicine, Kateb University, Kabul, Afghanistan
1 shared publication - Eaman Fatima
CMH Institute of Medical Sciences, Multan, Pakistan
1 shared publication - Laiba Jalal
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
Temporal trends and socio-demographic disparities in COPD–lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999–2020)
Background Chronic Obstructive Pulmonary Disease (COPD) and lung cancer remain among the leading causes of mortality worldwide, with a high burden reported in the United States. While both conditions often coexist and share risk factors such as smoking and environmental exposure, temporal mortality trends and disparities across demographics remain underexplored. Objective To analyze age-adjusted mortality rates (AAMRs) associated with the co-occurrence of COPD and lung cancer (COPD–LC) in the United States from 1999 to 2020, with a specific focus on temporal shifts and disparities across sex, race/ethnicity, and geographic regions. Methods Mortality data were retrieved from the CDC WONDER database. The underlying causes of death were identified using ICD-10 codes (J40–J44 for COPD and C33–C34 for lung cancer). AAMRs were standardized to the 2000 U.S. population. Joinpoint regression analysis was used to calculate Annual Percent Changes (APCs) and identify statistically significant shifts in mortality trends. Subgroup analyses were conducted by sex, race/ethnicity, and census regions. Mortality associated with the co-occurrence of COPD and lung cancer was identified using multiple-cause-of-death coding. Results A total of 587,762 deaths involving co-occurring chronic obstructive pulmonary disease (COPD) and lung cancer were identified in the United States between 1999 and 2020. Overall age-adjusted mortality rates (AAMRs) declined from 8.904 per 100,000 population in 1999 to 7.128 in 2020. Joinpoint regression demonstrated a three-segment trend, including a non-significant decline from 1999 to 2006 (APC: − 0.40), a significant decline from 2006 to 2018 (APC: − 1.77%), and a non-significant increase from 2018 to 2020 (APC: 0.71%). Sex-stratified analysis showed persistently higher mortality among males, although mortality declined more substantially in males than in females over time. Non-Hispanic White individuals demonstrated the highest mortality burden, whereas Asian or Pacific Islander and Hispanic populations had the lowest AAMRs. Regionally, mortality rates remained highest in the Midwest and South, while the West exhibited the steepest decline. Non-metropolitan areas demonstrated persistently elevated mortality rates compared with metropolitan regions. Conclusion While mortality among individuals with co-occurring COPD and lung cancer has declined significantly over two decades, demographic disparities based on sex, race, and geography persist. These findings highlight the need for equity-driven public health interventions and early detection strategies tailored to high-risk populations. Graphical abstract
- 30 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
Open AccessTemporal trends and socio-demographic disparities in COPD–lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999–2020)
Background Chronic Obstructive Pulmonary Disease (COPD) and lung cancer remain among the leading causes of mortality worldwide, with a high burden reported in the United States. While both conditions often coexist and share risk factors such as smoking and environmental exposure, temporal mortality trends and disparities across demographics remain underexplored. Objective To analyze age-adjusted mortality rates (AAMRs) associated with the co-occurrence of COPD and lung cancer (COPD–LC) in the United States from 1999 to 2020, with a specific focus on temporal shifts and disparities across sex, race/ethnicity, and geographic regions. Methods Mortality data were retrieved from the CDC WONDER database. The underlying causes of death were identified using ICD-10 codes (J40–J44 for COPD and C33–C34 for lung cancer). AAMRs were standardized to the 2000 U.S. population. Joinpoint regression analysis was used to calculate Annual Percent Changes (APCs) and identify statistically significant shifts in mortality trends. Subgroup analyses were conducted by sex, race/ethnicity, and census regions. Mortality associated with the co-occurrence of COPD and lung cancer was identified using multiple-cause-of-death coding. Results A total of 587,762 deaths involving co-occurring chronic obstructive pulmonary disease (COPD) and lung cancer were identified in the United States between 1999 and 2020. Overall age-adjusted mortality rates (AAMRs) declined from 8.904 per 100,000 population in 1999 to 7.128 in 2020. Joinpoint regression demonstrated a three-segment trend, including a non-significant decline from 1999 to 2006 (APC: − 0.40), a significant decline from 2006 to 2018 (APC: − 1.77%), and a non-significant increase from 2018 to 2020 (APC: 0.71%). Sex-stratified analysis showed persistently higher mortality among males, although mortality declined more substantially in males than in females over time. Non-Hispanic White individuals demonstrated the highest mortality burden, whereas Asian or Pacific Islander and Hispanic populations had the lowest AAMRs. Regionally, mortality rates remained highest in the Midwest and South, while the West exhibited the steepest decline. Non-metropolitan areas demonstrated persistently elevated mortality rates compared with metropolitan regions. Conclusion While mortality among individuals with co-occurring COPD and lung cancer has declined significantly over two decades, demographic disparities based on sex, race, and geography persist. These findings highlight the need for equity-driven public health interventions and early detection strategies tailored to high-risk populations. Graphical abstract
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14558-14560
Operating on the self-power, intimacy, and personhood in neurosurgery
Neurosurgery occupies a unique position in medicine because it intervenes directly on the biological basis of thought, behavior, and identity. While...
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14558-14560
Open AccessOperating on the self-power, intimacy, and personhood in neurosurgery
Neurosurgery occupies a unique position in medicine because it intervenes directly on the biological basis of thought, behavior, and identity. While...
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
Hydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future Directions
Glioblastoma multiforme (GBM) remains one of the most challenging malignancies to treat, characterized by extreme heterogeneity, therapeutic resistance, and a dismal prognosis. Current multimodal treatments frequently fail due to the tumor’s complex epigenetic landscape, infiltrative nature, and a highly hypoxic microenvironment that fosters immune evasion. This review evaluates the potential of repurposing hydralazine, a long-established FDA-approved vasodilator, as a novel epigenetic and metabolic modulator for GBM. Mechanistically, hydralazine acts as a non-nucleoside inhibitor of DNA methyltransferase (DNMT), facilitating the demethylation and reactivation of silenced tumor suppressor genes, such as p16 and GSTP1. Beyond its epigenetic effects, it influences tumor metabolism by modulating the adenosine signaling axis and inducing vascular dynamics—specifically the “vascular steal” phenomenon—that alter intratumoral oxygenation. These pleiotropic actions provide a compelling rationale for its use in sensitizing glioblastoma cells to conventional radiotherapy and chemotherapy. However, significant pharmacological hurdles, including uncertain blood-brain barrier penetration, a short plasma half-life, and risks of systemic toxicity such as drug-induced lupus, suggest that hydralazine is unlikely to be effective as a stand-alone clinical therapy. In conclusion, while hydralazine faces clear translational pitfalls as a monotherapy, its ability to strategically reshape the GBM biological landscape positions it as a valuable adjunctive agent. Future innovation must focus on optimizing central nervous system delivery and identifying biology-driven combination strategies to overcome the adaptive resistance of this aggressive disease.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessHydralazine as a Repurposed Epigenetic and Metabolic Modulator in Glioblastoma: Promise, Pitfalls, and Future Directions
Glioblastoma multiforme (GBM) remains one of the most challenging malignancies to treat, characterized by extreme heterogeneity, therapeutic resistance, and a dismal prognosis. Current multimodal treatments frequently fail due to the tumor’s complex epigenetic landscape, infiltrative nature, and a highly hypoxic microenvironment that fosters immune evasion. This review evaluates the potential of repurposing hydralazine, a long-established FDA-approved vasodilator, as a novel epigenetic and metabolic modulator for GBM. Mechanistically, hydralazine acts as a non-nucleoside inhibitor of DNA methyltransferase (DNMT), facilitating the demethylation and reactivation of silenced tumor suppressor genes, such as p16 and GSTP1. Beyond its epigenetic effects, it influences tumor metabolism by modulating the adenosine signaling axis and inducing vascular dynamics—specifically the “vascular steal” phenomenon—that alter intratumoral oxygenation. These pleiotropic actions provide a compelling rationale for its use in sensitizing glioblastoma cells to conventional radiotherapy and chemotherapy. However, significant pharmacological hurdles, including uncertain blood-brain barrier penetration, a short plasma half-life, and risks of systemic toxicity such as drug-induced lupus, suggest that hydralazine is unlikely to be effective as a stand-alone clinical therapy. In conclusion, while hydralazine faces clear translational pitfalls as a monotherapy, its ability to strategically reshape the GBM biological landscape positions it as a valuable adjunctive agent. Future innovation must focus on optimizing central nervous system delivery and identifying biology-driven combination strategies to overcome the adaptive resistance of this aggressive disease.